HRT for Menopause: Matching Treatment to Your Symptoms

• HRT is the most effective treatment for moderate-to-severe hot flushes and night sweats, cutting their frequency by roughly 70–90%.
• Started within 10 years of your last period or before age 60, HRT has a favourable benefit-risk balance for most healthy women with troublesome symptoms.
• If you still have your uterus and take systemic estrogen, you also need a progestin to protect the womb lining — this is non-negotiable.
• Transdermal estrogen (patch or gel) carries a lower clot risk than tablets and is preferred if you have cardiovascular risk factors, are overweight, smoke, or get migraine with aura.
• Vaginal estrogen is a separate, very low-risk treatment for vaginal dryness and urinary symptoms — it can be used on its own, alongside HRT, or even by many breast cancer survivors with oncology input.
• The old '5-year limit' is outdated. Duration is individualised and reviewed roughly once a year — there is no universal cut-off.

HRT replaces the estrogen (and, when needed, progesterone) that your ovaries stop producing around menopause. By topping up these hormones it eases the symptoms driven by estrogen decline. It is a treatment for symptoms and quality of life — not a youth tonic and not something every woman needs.

HRT is best supported for a few specific situations:

Most women reach for it because of vasomotor symptoms — hot flushes and night sweats. HRT is the most effective option here, typically reducing how often and how severely they happen by 70–90%. Indian Menopause Society data suggest most perimenopausal and early-postmenopausal Indian women get some vasomotor symptoms, and a meaningful minority have moderate-to-severe ones that disrupt sleep, work and daily life.

It also treats the genitourinary syndrome of menopause (GSM) — vaginal dryness, thinning, painful sex and bladder symptoms. For this, low-dose vaginal estrogen is usually more effective than systemic HRT and carries far less risk.

For women with premature ovarian insufficiency (before 40) or early menopause (before 45), HRT is not optional — it replaces hormones that should still be present and protects bones, heart and brain. It is generally continued at least to the usual menopause age of about 51 and then reviewed.

HRT can also help mood symptoms that are clearly hormonally driven in perimenopause, and it protects bone during the years it is used. It is not a first-line osteoporosis drug when other options exist, but it does reduce fracture risk.

Whether HRT suits you is a balance of several factors, not a simple yes or no. Understanding the framework helps you take part in the decision rather than just receive it.

When HRT is usually appropriate: symptomatic women within 10 years of their last period or under 60, with no major contraindications. This is where the benefit-risk balance is most favourable.

When it needs caution and tailoring: women with relative contraindications can often still use HRT with modifications — for example, a patch or gel instead of tablets to lower clot risk — and closer monitoring.

When it is generally avoided: absolute contraindications include current or recent breast cancer, other estrogen-sensitive cancers, a current or recent blood clot (deep vein thrombosis or pulmonary embolism), recent heart attack or stroke, severe active liver disease, undiagnosed vaginal bleeding (this must be investigated first), and pregnancy.

Why timing matters. Re-analysis of the Women's Health Initiative (WHI) data gave rise to the 'timing hypothesis': HRT started early in menopause (within about 10 years, or before 60) has a more favourable cardiovascular profile than HRT first started many years later. Starting fresh HRT after 60 purely for prevention is generally not recommended, though women already established on it can often continue with review.

Factors that raise risk and call for careful discussion include age over 60 at initiation, obesity, smoking, high blood pressure, diabetes, and a personal or family history of clots. Your doctor will weigh these against how much your symptoms affect your life.

The Indian context. Many women hesitate because of dated fears about cancer, a preference for 'natural' approaches, family attitudes, or simple reluctance to discuss menopause openly. These are valid to raise. The growth of menopause-focused gynaecology in Indian cities means there is now far better access to balanced, current HRT counselling than a generation ago. For some couples, talking about menopause at home is part of making this decision comfortably.

Estrogen is the main symptom-relieving part of HRT. It comes in different molecules and routes, and the route in particular changes the safety profile.

Oral tablets. Convenient and often the most affordable. Options in India include bioidentical estradiol (such as Progynova) and conjugated equine estrogens (Premarin). The catch: swallowed estrogen passes through the liver first, which slightly raises clotting factors and therefore clot risk, and modestly increases gallstone risk.

Transdermal — patches and gels. Estradiol delivered through the skin (patches like Estraderm or Climara; gels like Estrogel or Oestrogel) skips that first liver pass. The result is a lower clot risk than tablets, steadier hormone levels, and less effect on the liver. It costs more than generic tablets but is increasingly chosen first — and is preferred if you have cardiovascular risk factors, are overweight, smoke, have high blood pressure, or get migraine with aura.

Vaginal estrogen. A low dose delivered directly to vaginal tissue (creams, tablets or a ring). It treats vaginal dryness and GSM with minimal absorption into the bloodstream, so its safety profile is much more reassuring than systemic estrogen. It does not treat hot flushes — it is a local, not a whole-body, treatment.

Dose. The principle is the lowest dose that controls your symptoms, adjusted over about 6–8 weeks based on how you respond. Premature ovarian insufficiency usually needs higher, more physiological doses; older women or those with milder symptoms may do well on lower doses.

A note for vegetarian women: conjugated equine estrogens are derived from pregnant mare urine, which some women prefer to avoid. Plant-derived or synthetically made bioidentical estradiol (oral or transdermal) is an equally effective alternative.

If you still have your uterus and take systemic estrogen, you must also take a progestin. This is not optional. Estrogen on its own thickens the womb lining and, over time, raises the risk of endometrial hyperplasia and endometrial cancer four- to eight-fold. A progestin opposes that effect and keeps the lining safe. (Women who have had a hysterectomy can usually take estrogen alone.)

The preferred options today are the ones closest to your body's own hormone, because they have the most favourable safety profiles:

• Micronised progesterone (such as Mitogest, Susten, Naturogest) — the same molecule your ovaries make. Often taken at bedtime, where its mild sedating effect can actually help disrupted sleep.
• Dydrogesterone (Duphaston) — a close relative of natural progesterone with a clean profile.

Different symptoms respond best to different approaches. Naming your most troublesome symptoms helps you and your doctor target treatment precisely.

Hot flushes and night sweats. Systemic estrogen at an adequate dose, with a progestin if you have a uterus. Expect substantial relief within 6–12 weeks. Route depends on your risk factors. If HRT is unsuitable, non-hormonal options below can help.

Vaginal dryness, painful sex, urinary symptoms (GSM). Vaginal estrogen is the most effective treatment and can be added even when you are on systemic HRT, because the systemic dose may not fully reach urogenital tissue. Non-hormonal vaginal moisturisers and lubricants help too. This is also where painful sex after menopause is most fixable — yet cultural reticence means many Indian women suffer in silence.

Disrupted sleep. Often driven by night sweats. Treating those with estrogen, plus bedtime micronised progesterone and good sleep habits, resolves most cases. Persistent insomnia may need CBT for insomnia; do not ignore possible sleep apnoea, which is more common after menopause. Our guide to sleep in your 50s covers the practical habits.

Mood changes. For fluctuating perimenopausal irritability and low mood, HRT often helps, and micronised progesterone tends to be the best-tolerated progestin. True clinical depression still needs proper treatment — see coping with menopausal mood swings.

Brain fog. HRT may help when fog is tied to poor sleep or hot flushes; otherwise address sleep, thyroid, vitamin B12 and vitamin D. More in menopause brain fog.

Joint aches and other symptoms. Many women find perimenopausal joint pain eases on HRT, alongside exercise and weight management. HRT can also help libido indirectly by treating dryness and sleep; persistent low sex drive may have other contributors. For weight, HRT does not generally cause perimenopausal weight gain, which is driven mainly by ageing and muscle loss.

The popular image of HRT as 'dangerous' largely comes from early 2002 headlines about the WHI study. Decades of further research have produced a far more nuanced picture. Here is what the evidence supports.

Breast cancer. Combined HRT is linked to a modest increase in breast cancer risk after about 3–5 years of use — in absolute terms, an estimated 8 extra cases per 10,000 women per year. The risk is influenced by which progestin is used (micronised progesterone and dydrogesterone appear lower-risk than older synthetics) and it falls again after stopping. Estrogen-only HRT, used by women without a uterus, does not appear to raise breast cancer risk — long-term WHI follow-up even suggested a possible decrease. Stay up to date with breast cancer screening and mammogram timing in India while on HRT.

Blood clots (VTE). Oral HRT modestly raises clot risk — roughly 2–3 extra events per 10,000 women per year in women aged 50–59. Transdermal estrogen (patch or gel) does not carry this excess risk, which is why it is preferred when clot risk factors are present.

Heart and stroke. This is where timing matters most. Started within 10 years of menopause or before 60, HRT is broadly neutral-to-favourable for the heart. Started much later, it modestly raises cardiovascular risk, especially stroke. Transdermal looks more favourable than oral.

Endometrial (womb) cancer. Estrogen alone sharply raises this risk — which is exactly why a progestin is mandatory for women with a uterus. With adequate progestin or a hormonal IUD, the risk is not increased. Any unexpected bleeding on HRT needs evaluation, often a transvaginal ultrasound.

Putting it in proportion. For appropriate candidates, the absolute risks are small and the symptom benefits are large. The product, route, dose and timing you choose all shape the risk — which is why HRT is a personalised, shared decision rather than a blanket yes or no.

There is no universal time limit. The old advice to stop at 5 years reflected an over-cautious reading of early WHI data and has been set aside by current guidance from the International Menopause Society, the British Menopause Society, NICE, the Menopause Society (North America), FOGSI and IMS-India.

Instead, duration is individualised and reviewed about once a year. For women with ongoing symptoms and an acceptable risk profile, continuing for many years — sometimes throughout life — is reasonable. Many women use HRT for 5–10 years through the symptomatic window and then taper.

Premature ovarian insufficiency is treated until at least the usual menopause age (around 51), then reviewed like anyone else.

Vaginal estrogen is in a category of its own: because almost none reaches the bloodstream, it can be continued indefinitely, and many women appropriately use it for decades.

Stopping. A gradual taper over several months is gentler than stopping abruptly and reduces the chance of symptoms rebounding. If symptoms return strongly and affect your quality of life, restarting is reasonable. If they stay manageable, you can stay off. Some women cycle on and off as their symptoms ebb and flow.

Any new contraindication — a breast cancer diagnosis, a clot, a major cardiovascular event — means a prompt review and usually stopping systemic HRT.

HRT is the most effective treatment for hot flushes, but it is not the only one — and some women cannot or prefer not to use it.

For hot flushes and night sweats:

• SSRIs and SNRIs at lower-than-antidepressant doses — paroxetine, venlafaxine, escitalopram — have good evidence for vasomotor symptoms and are a sensible choice if you also have mood symptoms or have had breast cancer. Effects appear within 2–4 weeks.
• Gabapentin at bedtime helps night sweats and sleep.
• Newer NK3-receptor antagonists (such as fezolinetant) target hot flushes directly and are an emerging non-hormonal class, not yet widely available in India.

• Regular physical activity, including strength training (the WHO suggests 150–300 minutes of moderate activity weekly).
• Modest weight loss can noticeably reduce hot flushes in women carrying extra weight.
• A Mediterranean-style diet, limiting common triggers like spicy food, caffeine and alcohol where they affect you.
• Cognitive behavioural therapy for menopause and mindfulness-based stress reduction both have evidence for symptoms and quality of life.
• Yoga, with its strong Indian tradition, has a growing evidence base for menopausal wellbeing.

Comprehensive HRT options are available across India at a wide range of prices, and access through both clinics and telemedicine has grown rapidly.

Rough monthly costs (indicative):

• Oral estradiol (Progynova) or conjugated estrogens (Premarin): about ₹200–700.
• Transdermal patches (Estraderm, Climara, Estradot): about ₹1,500–3,500. Gels (Estrogel, Oestrogel): about ₹1,000–2,000.
• Vaginal estrogen cream (Premarin): about ₹200–600 amortised, since one tube lasts months.
• Micronised progesterone (Mitogest, Susten): about ₹300–700. Dydrogesterone (Duphaston): about ₹200–400.
• Hormonal IUD: Mirena about ₹12,000–18,000 plus insertion; generics Eloira and Emily about ₹6,000–10,000 — spread over several years this is very economical.
• Combined tablets (Femoston, Trisequens, Kliogest): about ₹600–1,200.

The prescription is the start, not the end. Good outcomes come from review and adjustment.

The monitoring rhythm. A first review at 6–8 weeks to check response and side effects and fine-tune the dose; another at 3–4 months; then roughly annual visits. Each review covers your symptoms, any side effects, bleeding pattern, blood pressure, a clinical breast check, and mammography per age-appropriate guidelines.

Bleeding to report. On a sequential regimen, a predictable monthly bleed is expected. On a continuous regimen, irregular bleeding is common in the first few months then settles. Beyond that, any unexpected, heavy, or post-menopausal bleeding should be checked.

Side effects such as breast tenderness, bloating or mood changes often ease over the first months; if they persist, switching the progestin, the route or the dose usually helps.

Integrate, don't isolate. HRT works best as one part of midlife health. Keep up bone protection with calcium and vitamin D, which many Indian women are low in, weight-bearing and resistance exercise, and a DEXA bone-density scan when indicated. Stay current with cervical, breast and colorectal screening, look after sleep and mental health, and keep blood pressure and blood sugar in check.

With periodic review and a few sensible lifestyle anchors, HRT can make the menopause transition far more comfortable — and free you to get on with the rest of your life.

• NICE Guideline NG23: Menopause — diagnosis and management
• The Menopause Society (NAMS) — 2022 Hormone Therapy Position Statement
• British Menopause Society — HRT guidance and tools
• International Menopause Society — menopause information and recommendations
• Indian Menopause Society (IMS-India)
• ACOG — Hormone Therapy and Menopause
• Women's Health Initiative — study overview (NHLBI)